BS_29X4ZX6Q
high-grade glioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- high-grade glioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- high-grade glioma
- overall_survival_months
- 37.417871222076215
- age_years
- 8.049
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.438
- G2M_CHECKPOINT+0.417
- E2F_TARGETS+0.391
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.346
- MITOTIC_SPINDLE+0.271
- COAGULATION+0.267
- WNT_BETA_CATENIN_SIGNALING+0.257
- MYC_TARGETS_V1+0.255
- GLYCOLYSIS+0.242
- ANGIOGENESIS+0.239
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.322
- IL6_JAK_STAT3_SIGNALING-0.288
- INTERFERON_GAMMA_RESPONSE-0.279
- HEME_METABOLISM-0.271
- INTERFERON_ALPHA_RESPONSE-0.265
- ALLOGRAFT_REJECTION-0.215
- P53_PATHWAY-0.215
- INFLAMMATORY_RESPONSE-0.214
- APICAL_SURFACE-0.209
- ADIPOGENESIS-0.172
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518399 | — | E | 0.830 |
| 2 | SRR12202460 | — | — | 0.829 |
| 3 | ERR2598164 | fetal | fetal | 0.825 |
| 4 | ERR2598184 | fetal | fetal | 0.816 |
| 5 | ERR2598180 | fetal | fetal | 0.814 |
| 6 | 5572a203-73b9-4a85-b47d-af228abca5b1 | — | — | 0.806 |
| 7 | ERR2598166 | fetal | fetal | 0.795 |
| 8 | 20110025.TNBC | — | E | 0.782 |
| 9 | SRR650136 | — | — | 0.782 |
| 10 | BS_TZ5D0A7R | Supratentorial Ependymoma | — | 0.780 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.438 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.417 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.391 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.346 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.271 | Inavolisib | — uncovered |
| COAGULATION | 0.267 | Binimetinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.257 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.255 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.242 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.239 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.225 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.214 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.196 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.142 | Idelalisib | — uncovered |
| HYPOXIA | 0.112 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.090 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.050 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.050 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.039 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.038 | Remibrutinib | — uncovered |